Novo Nordisk stock (NVO) plunged approximately 15% after the Danish pharmaceutical giant posted better-than-expected 2025 results but delivered a weak 2026 outlook. The company reported full-year 2025... ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Core Viewpoint - Shares of obesity drugmakers and developers experienced a decline following Novo Nordisk's forecast of a sharper-than-expected sales decline for 2026, highlighting increasing competition in the weight-loss market [1] Group 1 - Novo Nordisk's forecast indicates a significant sales decline for 2026, which was unexpected by the market [1] - The forecast reflects the intensifying competition within the obesity drug market, which is becoming increasingly crowded [1]

Financial Performance - In 2025, Novo Nordisk served over 45.6 million people with serious chronic diseases, achieving global sales growth of 10.3% and operating profit growth of 6.0% at constant exchange rates[8]. - Reported sales growth for 2023 was 31.3%, with a constant exchange rate growth of 35.6%[100]. - Operating profit growth for 2023 was reported at 37.1%, with a constant exchange rate growth of 43.7%[100]. - Sales growth is projected to decline to 6.4% by 2025, with operating profit growth expected to be (0.5%) in the same year[100]. - Future sales growth in constant exchange rates is forecasted at 10.3% for 2025[100]. Executive Remuneration - The total Board remuneration for 2025 amounted to DKK 23.8 million, reflecting a 3% increase from DKK 23.0 million in 2024[21]. - Total executive remuneration in 2025 amounted to DKK 193.3 million, a 38% decrease from DKK 311.1 million in 2024, primarily due to lower performance on incentive programs[37]. - The total remuneration for CEO Maziar Mike Doustdar in 2025 was DKK 20.7 million, down 39% from DKK 57.1 million in 2024, with 47% being fixed and 53% variable[38]. - The total remuneration for Lars Fruergaard Jørgensen during his tenure as CEO in 2025 was DKK 22.2 million, with severance payments totaling DKK 42.9 million[42]. - The total remuneration for the CEO, CFO, and former CEO reflects a strategic shift in compensation policies, with a focus on aligning incentives with company performance[94]. Incentive Programs - The short-term incentive for Maziar Mike Doustdar in 2025 was set at 24.7% of the maximum incentive, equivalent to 2.96 months' base salary[14]. - The short-term incentive program (STIP) for 2025 resulted in a payout of 18.8% of the maximum for group performance, with the CEO receiving 24.7% and the CFO receiving 24.4% of their maximum potential[45]. - The long-term incentive programme for 2023 achieved 92% of the maximum allocation, while performance for LTIP 2024 and LTIP 2025 is tracking below targets due to reduced financial performance[14]. - The long-term incentive program for 2025 is share-based with a three-year performance period, tracking below targets after the first year due to challenges faced[41]. - The average annual sales growth performance for the LTIP 2023-2025 was 24%, resulting in a maximum payout of 33%[72]. Board Governance - The Board of Directors reduced its size from 12 to 9 members following the Extraordinary General Meeting in November 2025[20]. - The remuneration policy for the Board of Directors was benchmarked against Nordic general industry and European pharma companies, with the Chair's fees above the upper quartile[29]. - The Remuneration Committee will not propose changes to the Remuneration Policy for adoption at the Annual General Meeting in March 2026[16]. - The Board's assessment of executive remuneration considers market benchmarks and the balance between fixed and variable pay[44]. - The company plans to present the Remuneration Report for an advisory vote at the Annual General Meeting in 2026[106]. Environmental Impact - Novo Nordisk's CO2e emissions increased by 19% in 2025 compared to 2024, primarily due to construction and expansion activities[9]. - The portion of expensed total remuneration linked to climate-related performance in 2025 is 1%[88]. Shareholder Information - The total shareholdings of Board members at the end of 2025 amounted to 588,712 shares, with a market value of DKK 191.6 million[35]. - As of December 31, 2025, executives held a total of 784,263 shares, with a market value of DKK 255.1 million[85]. - The share price decreased by 32.4% during the performance period (2023-2025), aligning the interests of shareholders and executives[73]. - The share price development from the grant in February 2023 to the end of 2025 shows a decline from DKK 481.00 to DKK 325.25, reflecting a negative performance adjustment[77]. Employee Remuneration - The average annual employee remuneration excluding registered executives in the parent company increased from DKK 0.85 million in 2021 to DKK 1.12 million in 2025, reflecting a growth of 31.8% over the five-year period[99]. - The average remuneration growth for the parent company was 1.8% in 2021, 4.4% in 2022, 8.6% in 2023, 5.2% in 2024, and projected at 10.1% in 2025[99]. - The average employee remuneration excluding registered executives in the group increased from DKK 0.79 million in 2021 to DKK 1.01 million in 2025[99]. - The CEO/Employee ratio for the group was 74 in 2021 and is projected to be 37 in 2025, reflecting a significant change in the compensation structure[99].

诺和诺德董事会已决定启动一项高达150亿丹麦克朗的新股票回购计划。 来源：滚动播报 ...

Danish drug maker Novo Nordisk said on Wednesday it had appointed Jamey Millar head of its U.S. business, and Hong Chow head of product and portfolio strategy. ...

本文源自：金融界AI电报 诺和诺德(NVO.N)股价跌幅持续扩大，现跌超13%。 ...

Core Insights - The Danish drugmaker anticipates a decline in adjusted sales between 5% and 13% at constant exchange rates for 2026, marking a significant reversal from the previous year when sales experienced a growth of 10% [1] Company Performance - The company reported a sales growth of 10% in the previous year, indicating a strong performance prior to the expected decline in 2026 [1] - The projected decline in sales for 2026 suggests potential challenges ahead for the company, contrasting sharply with the growth trend observed last year [1] Market Outlook - The anticipated sales decline reflects broader market conditions and may impact the company's competitive positioning within the pharmaceutical industry [1] - The shift from growth to decline could influence investor sentiment and market expectations regarding the company's future performance [1]

本文源自：金融界AI电报 诺和诺德预计本财年净利润为1024亿丹麦克朗。 ...

本文源自：金融界AI电报 诺和诺德预计本财年销售额为3090.64亿丹麦克朗，低于市场预估的3430.17亿丹麦克朗；预计本财年营 业利润为1276.58亿丹麦克朗。 ...